Twenty-one months into his second tenure as CEO of Bausch + Lomb, serial dealmaker Brent Saunders has so far come up empty in his latest attempt to sell the company. But it hasn’t been for lack of trying.
privacy policy | terms of use | contact us | advertise | pharma blogs | facebook | twitter
Copyright © 2025,